title: Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease.
abstract: OBJECTIVE
  To assess the utility of an autologous CD34(+) and CD133(+) stem cells infusion as a possible therapeutic modality in patients with end-stage liver diseases.
  
  
  METHODS
  One hundred and forty patients with end-stage liver diseases were randomized into two groups. Group 1, comprising 90 patients, received granulocyte colony stimulating factor for five days followed by autologous CD34(+) and CD133(+) stem cell infusion in the portal vein. Group 2, comprising 50 patients, received regular liver treatment only and served as a control group.
  
  
  RESULTS
  Near normalization of liver enzymes and improvement in synthetic function were observed in 54.5% of the group 1 patients; 13.6% of the patients showed stable states in the infused group. None of the patients in the control group showed improvement. No adverse effects were noted.
  
  
  CONCLUSIONS
  Our data showed that a CD34(+) and CD133(+) stem cells infusion can be used as supportive treatment for end-stage liver disease with satisfactory tolerability.
authors.affiliation: Tropical Medicine Department, El-Kasr Al-Aini School of Medicine, Kasr Al-Aini st., Kasr Al-Aini, 11977 Cairo, Egypt.
authors.forename: Hosny
authors.initials: H
authors.lastname: Salama
authors.forename: Abdel-Rahman N
authors.initials: AR
authors.lastname: Zekri
authors.forename: Abeer A
authors.initials: AA
authors.lastname: Bahnassy
authors.forename: Eman
authors.initials: E
authors.lastname: Medhat
authors.forename: Hanan A
authors.initials: HA
authors.lastname: Halim
authors.forename: Ola S
authors.initials: OS
authors.lastname: Ahmed
authors.forename: Ghada
authors.initials: G
authors.lastname: Mohamed
authors.forename: Sheren A
authors.initials: SA
authors.lastname: Al Alim
authors.forename: Ghada M
authors.initials: GM
authors.lastname: Sherif
mesh_terms: D000071916:AC133 Antigen; D000328:Adult; D015703:Antigens, CD / Q000276:immunology*; D018952:Antigens, CD34 / Q000276:immunology*; D058625:End Stage Liver Disease / Q000188:drug therapy / Q000601:surgery*; D005260:Female; D006023:Glycoproteins / Q000276:immunology*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000502:physiology*; D006801:Humans; D008099:Liver / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000276:immunology*; D011994:Recombinant Proteins; D015996:Survival Rate; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D018952:Antigens, CD34; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor